Financials data is unavailable for this security.
View more
Year on year Alligator Bioscience AB had net income fall 28.53% from a loss of 193.40m to a larger loss of 248.59m despite a 62.78% increase in revenues from 35.70m to 58.11m.
Gross margin | -- |
---|---|
Net profit margin | -512.61% |
Operating margin | -503.48% |
Return on assets | -136.02% |
---|---|
Return on equity | -417.18% |
Return on investment | -367.94% |
More ▼
Cash flow in SEKView more
In 2023, cash reserves at Alligator Bioscience AB fell by 31.19m. Cash Flow from Financing totalled 161.56m or 278.04% of revenues. In addition the company used 189.29m for operations while cash used for investing totalled 2.46m.
Cash flow per share | -0.3412 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.0125 |
---|---|
Tangible book value per share | -0.0362 |
More ▼
Balance sheet in SEKView more
Current ratio | 0.6707 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 5.17 |
More ▼